| JAMA: Candesartan linked to better survival in heart failure than losartan. |
|
| EurekAlert: (JAMA) In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years, according to a study in the January 12 issue of JAMA. |